Cancer News and Research

Latest Cancer News and Research

Study finds 15-year outcomes of BCT and mastectomy similar

Two studies to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday) and tomorrow (Saturday), shed light on the treatment options facing women carrying the BRCA1 and BRCA2 genetic mutations which predispose them to breast cancer.

26 Mar 2010

NCMHD announces $3.8M grant for research on minority recruitment in cancer clinical trials

The University of Minnesota Medical School today announced the details of a $3.8 million grant by the National Institutes of Health's National Center on Minority Health and Health Disparities for research focused on minority recruitment and retention in cancer clinical trials.

26 Mar 2010

Marijuana must not be legalized in California, says opposition to the legalization initiative

The Opposition to the California Marijuana Legalization Initiative (2010) has learned that the ballot measure for The Regulate, Control and Tax Cannabis Act of 2010 has officially been certified by the State of California to qualify for the November ballot.

26 Mar 2010

Presence of protein PARP in tumours may help predict response to chemotherapy

The presence of the protein poly (ADP-ribose) polymerase (PARP) in tumours can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona tomorrow (Saturday 27 March). Professor Gunter von Minckwitz, from the German Breast Group Forschungs GmBH, Neu-Isenburg, says that, contrary to current belief that PARP is associated with a limited number of tumours, he and his team found for the first time that PARP expression exists across all breast cancer subtypes, and that such tumours were highly sensitive to chemotherapy.

26 Mar 2010

Disparities in African American women's breastfeeding practices

African American women are less likely to breastfeed their children, in part due to the preconceived attitudes that women have regarding breastfeeding vs. formula feeding, according to a new study from Cincinnati Children's Hospital Medical Center researchers.

26 Mar 2010

Survival rate is improving in HER2 positive breast cancer patients

Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumours are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say today (Friday 26 March) at the seventh European Breast Cancer Conference.

26 Mar 2010

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

British researchers have discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics. The study has found that an abnormality on chromosome 17, called CEP17, is not only associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumour will respond to anthracyclines. The research will be presented at the European Breast Cancer Conference (EBCC7) Thursday 25th March.

26 Mar 2010

Treatment with beta-blockers can help reduce spread of cancer in patients with breast tumours

Treatment with beta-blockers can help reduce the spread of cancer in patients with breast tumours, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today (Friday).

26 Mar 2010

American Academy of Actuaries to work with regulatory authorities to enhance quality of care

With the enactment of health care reform legislation yesterday, the American Academy of Actuaries said the successful implementation of this and forthcoming reconciliation legislation will require coordinated efforts to ensure that the regulatory development process accomplishes the intended goals of reform.

26 Mar 2010

Evaluating potential of Ampligen and TLR3 agonists as cancer immunotherapeutics

Hemispherx Biopharma, Inc., announced today the publication of an editorial entitled "TLR3 agonists as immunotherapeutic agents," published in the March 15, 2010 edition of Immunotherapy (2010) 2(2), 137-140, co-authored by Jonathan S. Berek, MD, Chairman, Stanford University School of Medicine Department of Obstetrics and Gynecology, and Christopher F. Nicodemus, MD, Chairman and Chief Scientific Officer, Advanced Immune Therapeutics, Inc., and HEB Consultant.

26 Mar 2010

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Celera Corporation today announced the publication of data reporting that elderly (over age 70) carriers of the KIF6 gene variant with prior vascular disease received significant benefit from pravastatin (Pravachol®) therapy. Previous research has shown that a variant of the KIF6 gene, a member of the molecular motor protein kinesin family, is associated with up to a 55% increased risk of primary and recurrent coronary heart disease (CHD) events in the placebo arms of the clinical trials, and that this increased risk is virtually eliminated with statin therapy.

26 Mar 2010

Budget continues to ignore mental illness and sanctions deaths of young Ontarians

Suicide is the leading cause of non-accidental death in Ontario's youths aged 10 to 19, claiming the lives of our young people more than any other health-related cause. Mental illness is the strongest risk factor for suicide yet these youths cannot get treatment because of years of government underfunding.

26 Mar 2010

Researchers made vital discovery in the development of new drug to cure TB

This World TB Day (March 24), researchers at Sydney's Centenary Institute announce they have made an exciting discovery that could lead to the first new drug for Tuberculosis (TB) in almost fifty years.

26 Mar 2010

Lung transplant patients may one day benefit from synthetic peptide, researchers report

Lung transplant patients may one day benefit from a synthetic peptide that mimics the body's natural ability to reduce excess fluid accumulation, Medical College of Georgia researchers report.

26 Mar 2010

UK government commits £250M for proposed medical research and innovation centre

Gordon Brown has announced the government's commitment to investing £250 million in the proposed UK Centre for Medical Research and Innovation (UKCMRI).

26 Mar 2010

Informing young women surviving breast cancer about opportunities to have children

At a time when more and more young women are surviving breast cancer and delaying childbirth, it is important to take their needs and wishes about their future fertility into consideration when deciding on treatment, the seventh European Breast Cancer Conference (EBCC7) in Barcelona will hear today.

26 Mar 2010

False perception of increased risk induces women with breast cancer have prophylactic mastectomies

Women who have been diagnosed with breast cancer believe the risk of the disease occurring in their unaffected breast is as much as ten times higher than it actually is. As a result, they are choosing to have prophylactic mastectomies based on a false perception of increased risk, according to new research.

26 Mar 2010

Most transplant candidates agree to receive kidney from donor at increased risk of viral infection

Most kidney transplant candidates are willing to receive a kidney from a donor at increased risk of viral infection, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results suggest that kidney disease patients can make rational tradeoffs between the virtues and risks conferred by donated kidneys.

26 Mar 2010

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Genmab A/S announced today that on March 23, 2010 Genentech, Inc. and Biogen Idec, Inc. filed a declaratory relief complaint at the US District Court, Southern District of California against Genmab's collaboration partner GlaxoSmithKline (GSK) for patent infringement under US patent No 7,682,612 based on GSK's manufacture, marketing and sale of Arzerra™ in the United States for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).

26 Mar 2010

Adjuvant systemic must be considered for treatment of primary breast cancer and recurrence

Recurrence of breast cancer in the same area as the original tumour remains the strongest, independent prognostic factor for subsequent metastasis and death, even for patients who have been free of disease for a very long time, according to research presented today (Wednesday) at the seventh European Breast Cancer Conference (EBCC7).

26 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Study finds 15-year outcomes of BCT and mastectomy similar

NCMHD announces $3.8M grant for research on minority recruitment in cancer clinical trials

Marijuana must not be legalized in California, says opposition to the legalization initiative

Presence of protein PARP in tumours may help predict response to chemotherapy

Disparities in African American women's breastfeeding practices

Survival rate is improving in HER2 positive breast cancer patients

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

Treatment with beta-blockers can help reduce spread of cancer in patients with breast tumours

American Academy of Actuaries to work with regulatory authorities to enhance quality of care

Evaluating potential of Ampligen and TLR3 agonists as cancer immunotherapeutics

Pravastatin benefits elderly carriers of KIF6 gene variant with prior vascular disease

Budget continues to ignore mental illness and sanctions deaths of young Ontarians

Researchers made vital discovery in the development of new drug to cure TB

Lung transplant patients may one day benefit from synthetic peptide, researchers report

UK government commits £250M for proposed medical research and innovation centre

Informing young women surviving breast cancer about opportunities to have children

False perception of increased risk induces women with breast cancer have prophylactic mastectomies

Most transplant candidates agree to receive kidney from donor at increased risk of viral infection

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Adjuvant systemic must be considered for treatment of primary breast cancer and recurrence

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in